Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Split Won’t “Make Or Break” Pfizer, CEO Read Says

Executive Summary

The big pharma’s chief executive assured investors there is no expiration date on optionality, suggesting the company could always reconsider splitting up the business even if decides against such action this year.

Advertisement

Related Content

Stronger Together: Pfizer Decides Against A Split
Lilly's Abemaciclib Hit Leaves It Down But Not Out
Pfizer Dashes Hopes For A PCSK9 Pill
2Q Pharma Results Preview: Pfizer, Shire, Merck KGaA, Teva, Novo Nordisk And Allergan

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel